PGEN - Precigen stock jumps ~10% as CAR-T cell therapy's dosing starts in cancer trial
2023-03-29 12:30:01 ET
- Precigen ( NASDAQ: PGEN ) stock rose ~12% on Wednesday after the company said that the first patient was dosed in a phase 1/1b trial of PRGN-3007 to treat advanced ROR1-positive (ROR1 + ) blood and solid tumors.
- The target population for the trial includes patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), and diffuse large B-cell lymphoma (DLBCL) and solid tumors, including breast adenocarcinomas encompassing triple negative breast cancer (TNBC).
- Precigen noted that PRGN-3007 UltraCAR-T is a first-in-class investigational, autologous CAR-T cell therapy which uses the company's non-viral gene delivery system and an overnight, decentralized manufacturing process.
- "The PRGN-3007 study targets a broad range of hematological and solid tumor indications and this milestone helps us move closer to our vision for UltraCAR-T, which aims to deliver a library of personalized autologous UltraCAR-T therapies using overnight manufacturing at the patient's medical center," said Precigen President and CEO Helen Sabzevari.
For further details see:
Precigen stock jumps ~10% as CAR-T cell therapy's dosing starts in cancer trial